Nyvepria (Pegfilgrastim)

Nyvepria is a pegylated filgrastim product that supports the neutrophil recovery pathway in patients undergoing cytotoxic chemotherapy.

• Chemotherapy‑induced neutropenia: shortens the duration of low neutrophil counts and helps maintain dose intensity.
• Stem‑cell mobilization for autologous transplantation: facilitates collection of adequate CD34‑positive cells.
• Peripheral blood progenitor cell collection: improves yield of progenitor cells for transplantation.

• Pegfilgrastim is a pegylated form of recombinant human granulocyte‑colony stimulating factor (G‑CSF). The polyethylene glycol (PEG) chain prolongs circulating half‑life, allowing sustained activation of G‑CSF receptors on myeloid progenitor cells. Continuous receptor stimulation drives proliferation, differentiation and maturation of neutrophil precursors, leading to increased peripheral neutrophil counts.

Common Side Effects

• Bone pain: mild to moderate discomfort often reported in long bones.
• Injection‑site reactions: redness, swelling or itching at the administration site.
• Fatigue: general tiredness without a specific cause.
• Headache: transient mild headache.
• Nausea: occasional feeling of queasiness.
• Arthralgia: joint aches, usually low‑grade.

Serious or Rare Side Effects

• Splenic rupture: sudden abdominal pain with signs of internal bleeding.
• Acute respiratory distress syndrome (ARDS): severe breathing difficulty.
• Anaphylaxis: rapid onset of hives, swelling, airway compromise.
• Severe allergic reaction: systemic rash, fever, hypotension.
• Capillary leak syndrome: rapid fluid shift causing edema and low blood pressure.
• Severe bone pain requiring opioid analgesia.

Before using Nyvepria, consider the following safety measures:

• Renal impairment: adjust monitoring as reduced clearance may affect exposure.
• Hepatic dysfunction: observe for increased incidence of bone pain.
• Prior splenic injury or disease: avoid use due to risk of rupture.
• Concomitant chemotherapy: coordinate timing to optimise neutrophil recovery.
• Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed.
• Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Pegfilgrastim may interact with other agents that affect bone‑marrow function or immune response.

Major Interactions (Avoid)

• Cytotoxic chemotherapy administered within 24 h of pegfilgrastim: may reduce efficacy of both agents.
• Myelosuppressive antibiotics (e.g., chloramphenicol): can blunt neutrophil response.
• High‑dose steroids: may diminish the proliferative effect on neutrophils.

Moderate Interactions (Monitor Closely)

• Immunomodulatory drugs (e.g., lenalidomide): monitor blood counts closely.
• Anticoagulants: watch for increased bleeding if severe bone pain limits mobility.
• Live vaccines: immune response may be altered; assess timing relative to pegfilgrastia administration.